title: Effects of vasodilatory antihypertensive agents on endothelial dysfunction in rats with ischemic acute renal failure.
abstract: Ischemic acute renal failure is associated with vascular endothelial dysfunction. We examined whether vasodilatory antihypertensive agents would improve endothelial function in rats with ischemia/reperfusion renal injury. Rat kidneys were isolated and perfused after clipping of the bilateral renal arteries for 45 min and reperfusion for 24 h, and renal perfusion pressure and nitric oxide concentration in the venous effluent (chemiluminescence assay) were monitored. Preischemic administration of celiprolol (a beta-blocker; 100 mg/kg p.o.), benidipine (a calcium channel blocker; 1 mg/kg p.o.), or imidapril (an angiotensin converting-enzyme inhibitor; 3 mg/kg p.o.) restored endothelial function in rats subjected to acute renal ischemia (deltarenal perfusion pressure [10(-8) M acetylcholine]: sham -42+/-3%, ischemia -31+/-1%, ischemia +celiprolol -39+/-1%*, ischemia+benidipine -38+/-2%*, ischemia+imidapril -42+/-2%*; *p<0.05 vs. ischemia). Serum urea nitrogen and creatinine levels were also lower in the treated groups. Furthermore, ischemia-induced decreases in the response to acetylcholine and renal excretory function were smaller in SHR than in deoxycorticosterone-salt hypertensive rats, in which endothelial damage was marked. These results suggest that preischemic endothelial function may influence the degree of ischemic renal injury. Calcium channel blockers, converting-enzyme inhibitors, and endothelial NO synthase-activating beta-blockers had beneficial effects on renovascular endothelial dysfunction due to ischemia.
authors.affiliation: Department of Internal Medicine, University of Tokyo, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Kakoki
authors.forename: Y
authors.initials: Y
authors.lastname: Hirata
authors.forename: H
authors.initials: H
authors.lastname: Hayakawa
authors.forename: E
authors.initials: E
authors.lastname: Suzuki
authors.forename: D
authors.initials: D
authors.lastname: Nagata
authors.forename: H
authors.initials: H
authors.lastname: Nishimatsu
authors.forename: K
authors.initials: K
authors.lastname: Kimura
authors.forename: A
authors.initials: A
authors.lastname: Goto
authors.forename: M
authors.initials: M
authors.lastname: Omata
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology; D058186:Acute Kidney Injury / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D001806:Blood Urea Nitrogen; D001835:Body Weight; D002121:Calcium Channel Blockers / Q000494:pharmacology; D017272:Celiprolol / Q000494:pharmacology*; D003404:Creatinine / Q000097:blood; D003900:Desoxycorticosterone; D004095:Dihydropyridines / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism*; D007093:Imidazoles / Q000494:pharmacology; D048289:Imidazolidines; D008297:Male; D009569:Nitric Oxide / Q000378:metabolism; D051381:Rats; D011918:Rats, Inbred SHR; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D007093:Imidazoles; D048289:Imidazolidines; D014665:Vasodilator Agents; D009569:Nitric Oxide; D003900:Desoxycorticosterone; C061004:benidipine; D003404:Creatinine; C065166:imidapril; D017272:Celiprolol; D000109:Acetylcholine